Derek Maetzold Sells 3,622 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 3,622 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $20.66, for a total transaction of $74,830.52. Following the transaction, the insider owned 12,646 shares in the company, valued at approximately $261,266.36. This trade represents a 22.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Trading Down 1.0%

CSTL stock traded down $0.21 during midday trading on Wednesday, hitting $20.25. The stock had a trading volume of 310,438 shares, compared to its average volume of 394,666. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 6.53. The firm has a market cap of $614.18 million, a PE ratio of -46.02 and a beta of 1.04. Castle Biosciences, Inc. has a 12-month low of $14.59 and a 12-month high of $44.28. The company’s 50-day moving average price is $21.99 and its 200 day moving average price is $30.05.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.49) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.49). The company had revenue of $84.23 million for the quarter, compared to the consensus estimate of $79.23 million. Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. On average, equities research analysts predict that Castle Biosciences, Inc. will post -1.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Morgan Stanley raised shares of Castle Biosciences to a “buy” rating in a report on Monday, March 2nd. Canaccord Genuity Group cut their price target on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, April 20th. BTIG Research cut their target price on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. KeyCorp set a $35.00 price objective on shares of Castle Biosciences in a research note on Friday, May 29th. Finally, Zacks Research cut shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 26th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.83.

Institutional Trading of Castle Biosciences

Hedge funds have recently modified their holdings of the company. Federated Hermes Inc. acquired a new stake in shares of Castle Biosciences in the fourth quarter valued at approximately $26,000. Kemnay Advisory Services Inc. bought a new stake in shares of Castle Biosciences in the fourth quarter valued at about $35,000. Jones Financial Companies Lllp boosted its position in shares of Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after acquiring an additional 2,648 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Castle Biosciences by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after acquiring an additional 297 shares during the period. Finally, Russell Investments Group Ltd. boosted its position in shares of Castle Biosciences by 63.7% in the third quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock valued at $57,000 after acquiring an additional 976 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.